Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial quality control market. Growth Direct platform offers clear advantages over manual MQC, with automation, regulatory benefits, and a $10B addressable market opportunity. Merck partnership is a key catalyst, enabling global distribution, supply chain optimization, and improved gross margins for Rapid Micro Biosystems.
In the closing of the recent trading day, Merck (MRK) stood at $79.96, denoting a -1.91% move from the preceding trading day.
![]() 0QAH 1 month ago | Other | $0.81 Per Share |
![]() 0QAH 4 months ago | Other | $0.81 Per Share |
![]() 0QAH 7 months ago | Other | $0.81 Per Share |
![]() 0QAH 10 months ago | Other | $0.77 Per Share |
![]() 0QAH 17 Jun 2024 | Other | $0.77 Per Share |
29 Jul 2025 (In 6 days) Date | | 2.02 Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | - Cons. EPS | 1.48 EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
30 Jul 2024 Date | | - Cons. EPS | 2.14 EPS |
![]() 0QAH 1 month ago | Other | $0.81 Per Share |
![]() 0QAH 4 months ago | Other | $0.81 Per Share |
![]() 0QAH 7 months ago | Other | $0.81 Per Share |
![]() 0QAH 10 months ago | Other | $0.77 Per Share |
![]() 0QAH 17 Jun 2024 | Other | $0.77 Per Share |
29 Jul 2025 (In 6 days) Date | | 2.02 Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | - Cons. EPS | 1.48 EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
30 Jul 2024 Date | | - Cons. EPS | 2.14 EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Robert M. Davis CEO | LSE Exchange | US58933Y1055 ISIN |
US Country | 73,000 Employees | - Last Dividend | 3 Jun 2021 Last Split | 13 Jan 1978 IPO Date |
Merck & Co., Inc. is a global healthcare leader focused on innovating new solutions to tackle some of the most serious health challenges. Founded in 1891 and headquartered in Rahway, New Jersey, the company operates worldwide, engaging in the discovery, development, manufacturing, and marketing of pharmaceuticals and animal health products. It operates two main segments: Pharmaceutical and Animal Health. The Pharmaceutical segment is dedicated to developing and offering human health pharmaceutical products across a range of areas including oncology, cardiovascular, and diabetes, among others. The Animal Health segment works on veterinary pharmaceuticals, vaccines, and health management solutions and services. Merck serves a diverse clientele, including drug wholesalers, retailers, hospitals, government agencies, physicians, veterinarians, and pet owners. Notably, the company invests in several strategic collaborations and agreements with other pharmaceutical giants like AstraZeneca PLC and Bayer AG, aiming to enhance its product offerings and harness innovative treatments for multiple diseases.
The products and services offered by Merck & Co., Inc. span a broad spectrum of medical needs in both human and animal health sectors:
In the arena of collaborative efforts, Merck has entered into multiple significant agreements to bolster its product pipeline: